Climb Bio Inc (CLYM)

01:00 AM

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.

01:00 AM

Apr 04, 2026

Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart

Apr 04, 2026

Apr 03, 2026

Climb Bio announces departure of finance SVP and appointment of new accounting officer - Investing.com

Apr 03, 2026

Apr 03, 2026

Climb Bio's recently appointed CFO is unlikely to make a significant impact—what truly matters is the clinical data. - Bitget

Apr 03, 2026

Apr 03, 2026

Climb Bio Consolidates Financial Leadership After SVP Departure - TipRanks

Apr 03, 2026

Apr 03, 2026

Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - stocktitan.net

Apr 03, 2026

Apr 02, 2026

Climb Bio (CLYM) price target increased by 34.43% to 15.67 - MSN

Apr 02, 2026

Apr 02, 2026

CLYM Stock Price, Quote & Chart | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill

Apr 02, 2026

Mar 30, 2026

Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN

Mar 30, 2026

Mar 28, 2026

Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Mar 28, 2026

Mar 27, 2026

Climb Bio, Inc.Common Stock (NQ: CLYM - The Chronicle-Journal

Mar 27, 2026

Mar 26, 2026

Climb Bio (NASDAQ:CLYM) Raised to Strong-Buy at B. Riley Financial - MarketBeat

Mar 26, 2026

Mar 25, 2026

B Riley Securities initiates coverage of Climb Bio (CLYM) with buy recommendation - MSN

Mar 25, 2026

Mar 24, 2026

B. Riley Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $26 - Moomoo

Mar 24, 2026

Mar 24, 2026

B. Riley Financial Initiates Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat

Mar 24, 2026

Mar 24, 2026

B.Riley initiates Climb Bio stock with buy rating on kidney drug potential - Investing.com

Mar 24, 2026

Mar 24, 2026

B.Riley initiates Climb Bio stock with buy rating on kidney drug potential By Investing.com - Investing.com Australia

Mar 24, 2026

Mar 22, 2026

If You Invested $1,000 in Climb Bio (CLYM) - stocktitan.net

Mar 22, 2026

Mar 21, 2026

Aug Breakouts: Is Climb Bio Inc forming a double bottom2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn

Mar 21, 2026

Mar 19, 2026

Climb Bio (NASDAQ:CLYM) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat

Mar 19, 2026

Mar 18, 2026

Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - MSN

Mar 18, 2026

Mar 18, 2026

Climb Bio (CLYM) Receives 'Buy' Rating from Truist Securities | - GuruFocus

Mar 18, 2026

Mar 18, 2026

This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Mar 18, 2026

Mar 17, 2026

Truist initiates Climb Bio stock with buy rating on drug potential - Investing.com Australia

Mar 17, 2026

Mar 17, 2026

Truist initiates Climb Bio stock with buy rating on drug potential By Investing.com - Investing.com South Africa

Mar 17, 2026

Mar 17, 2026

Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday - marketbeat.com

Mar 17, 2026

Mar 14, 2026

Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - MarketBeat

Mar 14, 2026

Mar 13, 2026

HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings - Defense World

Mar 13, 2026

Mar 12, 2026

Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn

Mar 12, 2026

Mar 12, 2026

Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn

Mar 12, 2026

Mar 12, 2026

Raymond James initiates coverage of Climb Bio (CLYM) with strong buy recommendation - MSN

Mar 12, 2026